logo-loader
HealthPharma & Biotech
LBT Innovations Limited

LBT Innovations raises capital and generates sales leads in the US

LBT Innovations Limited (ASX:LBT) chief executive officer Brent Barnes updates Proactive Investors on developments to forge ahead with product sales of its unique APAS Independence technology. 
 
The ground-breaking medical technology company has also raised $5 million on the back of FDA clearance, which will enable the execution of commercialisation plans.
 
Barnes will attend this week's American Society of Microbiology Microbe meeting in San Francisco to further showcase the APAS Independence to the US and global markets.

Quick facts: LBT Innovations Limited

Price: 0.16 AUD

Market: ASX
Market Cap: $37.65 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Shield Therapeutics to present data showing Feraccru offers 'real oral...

Shield Therapeutics PLC's (LON:STX) Dr Mark Sampson speaks to Proactive London's Andrew Scott ahead of them presenting positive data from the Phase 3b, open-label randomised controlled trial of Feraccru. He says the trial shows the drug, also known as Accrufer in the States, offers a real...

14 hours, 55 minutes ago

2 min read